Maravai LifeSciences Holdings, (MRVI) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $5.08: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Elevated put/call ratio: 2.00; Below-average business quality.
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and... Read more
Sell if holding. Engine safety override at $5.08: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Elevated put/call ratio: 2.00; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.3/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 61d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-11Recent Developments — Maravai LifeSciences Holdings,
Latest news
- NEWS 12 Health Care Stocks Moving In Friday's Intraday Session — benzinga May 8, 2026 neutral
- NEWS Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $5.5 — benzinga May 8, 2026 positive
- NEWS 12 Health Care Stocks Moving In Thursday's After-Market Session — benzinga May 7, 2026 neutral
- NEWS Maravai LifeSciences Raises FY2026 Sales Guidance from $200.000M-$210.000M to $205.000M-$215.000M vs $204.933M Est — benzinga May 7, 2026 positive
- NEWS Maravai LifeSciences Q1 Adj. EPS $0.01 Beats $(0.05) Estimate, Sales $65.837M Beat $53.046M Estimate — benzinga May 7, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $5.08: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Elevated put/call ratio: 2.00; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $4.72. Score 5.3/10, moderate confidence.
Take-profit target: $5.19 (+2.2% upside). Prior stop was $4.72. Stop-loss: $4.72.
Target reached (-2.4% upside); Quality below floor (2.0 < 4.0).
Maravai LifeSciences Holdings, trades at a P/E of N/A (forward -54.8). TrendMatrix value score: 4.0/10. Verdict: Sell.
16 analysts cover MRVI with a consensus score of 3.9/5. Average price target: $6.
What does Maravai LifeSciences Holdings, do?Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug...
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.